Share this article
Share this article
INDIANAPOLIS, April 23, 2021 /PRNewswire/ Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company s (NYSE: LLY) Taltz
® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PASI) 100. In three real-world analyses of U.S. claims data ranging from one to three years, patients treated with Taltz stayed on treatment longer, were more adherent to the prescription and had more days on monotherapy compared to the other biologics studied. These results are being presented virtually at the American Academy of Dermatology s Virtual Meeting Experience (AAD VMX), April 23-25, 20
Incyte logo. (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, April 23, 2021 /PRNewswire/ Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte s (NASDAQ:INCY) OLUMIANT
® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, OLUMIANT provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by percent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with OLUMIANT showed significant improvements in the severity and extent of disease compared to placebo. In the integrated safety analysis o
Johnson & Johnson Consumer Health Reveals New Skin Health Research at American Academy of Dermatology VMX 2021
Sixteen Presentations Reinforce Johnson & Johnson Consumer Health s Deep Commitment to Science-Based Innovations for Skin Health
News provided by
Share this article
Share this article
SKILLMAN, N.J., April 23, 2021 /PRNewswire/ Johnson & Johnson Consumer Health will present new research including among the first of its kind study on restorative skincare for cancer patients, new advances in multicultural skincare, the emotional impact of acne, and more to the world s leading dermatologists at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) April 23-25, 2021. A total of 16 posters will be presented at this year s conference, including three oral presentations.
Johnson & Johnson Consumer Health Presents New Data on Skincare for Cancer Patients at the American Academy of Dermatology VMX 2021
New Study Results Indicate a Daily Avena Sativa (Oat) Skincare Regimen Significantly Improves Itch and Dry Skin in Adults Undergoing Systemic Cancer Treatments
News provided by
Share this article
Share this article
SKILLMAN, N.J., April 23, 2021 /PRNewswire/ Johnson & Johnson Consumer Health today presented findings from one of the first clinical studies examining a daily skincare regimen as adjunctive therapy for cancer patients at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021. The study shows a daily Avena Sativa (Oat) skincare regimen provided a significant improvement in xerosis and pruritus (dry skin and itch) for adult patients undergoing systemic oncology treatments, indicating Aveeno Restorative Skin Therapy is safe and effective for the management of mild-to-moderate itch and/or dry skin related to system
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla®
Significantly more patients treated with deucravacitinib achieved PASI 75 and sPGA 01 compared to patients treated with placebo and Otezla at Week 16, with an increased benefit versus Otezla at Week 24 and maintained through Week 52 Deucravacitinib was well tolerated with a low rate of discontinuation due to adverse events Deucravacitinib is a first-in-class, oral, selective tyrosine kinase 2 inhibitor with a unique … Significantly more patients treated with deucravacitinib achieved PASI 75 and sPGA 0/1 compared to patients treated with placebo and Otezla at Week 16, with an increased benefit versus Otezla at Week 24 and maintained through Week 52